<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148913</url>
  </required_header>
  <id_info>
    <org_study_id>2014-067</org_study_id>
    <nct_id>NCT02148913</nct_id>
  </id_info>
  <brief_title>Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma</brief_title>
  <official_title>A Phase I Study of Melphalan, Bendamustine, and Carfilzomib for Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing&#xD;
      autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and&#xD;
      carfilzomib. We hypothesize that the addition of carfilzomib to a conditioning regimen of&#xD;
      melphalan and bendamustine in the setting of autologous transplantation for multiple myeloma&#xD;
      is feasible and safe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.</time_frame>
    <description>An absence of neutrophil engraftment by Day +22, absence of platelet engraftment by Day +35, and any grade 4 GI toxicity or any &gt;/= grade 3 non-hematologic toxicity as defined by the common toxicity criteria, which is deemed by the DSMB as probably related to the study protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.</time_frame>
    <description>Engraftment of Neutrophils: ANC recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 109/L for three consecutive laboratory values obtained on different days. The day used as neutrophil engraftment is the date of the first of three laboratory values.&#xD;
Engraftment of Platelets: Platelet engraftment is defined as a platelet count ≥ 20 x 109/L for 3 consecutive measurements obtained on different days. The patient must not have received a platelet infusion for seven consecutive days prior to the first day being considered. The day used as platelet engraftment is the date of the first of three laboratory values.&#xD;
Graft Failure: Graft failure includes failure to achieve neutrophil engraftment by day 22.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Response Rate</measure>
    <time_frame>Disease assessment at day +100, +180, and +365 (+/- 7 days).</time_frame>
    <description>Find the response rate of the combination of melphalan, bendamustine, and carfilzomib as a conditioning regimen in patients with multiple myeloma undergoing autologous transplantation.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Carfilzomib 15 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Carfilzomib 20 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b: Carfilzomib 20 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Carfilzomib 27mgm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1: Carfilzomib 15 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6</description>
    <arm_group_label>Cohort 1: Carfilzomib 15 mg/m2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: Carfilzomib 20 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6</description>
    <arm_group_label>Cohort 2: Carfilzomib 20 mg/m2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2b: Carfilzomib 20 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5</description>
    <arm_group_label>Cohort 2b: Carfilzomib 20 mg/m2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3b: Carfilzomib 27 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5</description>
    <arm_group_label>Cohort 3: Carfilzomib 27mgm2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma&#xD;
&#xD;
          -  At least 2 x 106 CD34+ cells/kg have been collected from the patient and cryopreserved&#xD;
             for ASCT&#xD;
&#xD;
          -  Greater than 18 years&#xD;
&#xD;
          -  Karnofsky score greater than 70%&#xD;
&#xD;
          -  No evidence of progressive bacterial, viral, or fungal infection&#xD;
&#xD;
          -  Absolute neutrophil count above 1000&#xD;
&#xD;
          -  Platelet count above 50,000&#xD;
&#xD;
          -  Hemoglobin above 8 g/dL&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  Total bilirubin, ALT, and AST less than 2 x the upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase less than or equal to 250 IU/L&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) greater than or equal to 45%&#xD;
&#xD;
          -  Adjusted Carbon Monoxide Diffusing Capacity (DLCO) greater than or equal to 60%&#xD;
&#xD;
          -  Negative HIV serology&#xD;
&#xD;
          -  Recovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and&#xD;
             hematological toxicity)&#xD;
&#xD;
          -  Patients with a pre-transplant disease status consistent with a very good partial&#xD;
             response (VGPR), partial response (PR), stable disease (SD), progressive disease (PD),&#xD;
             or relapse from complete remission (CR).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are refractory to carfilzomib. Refractory is defined as disease&#xD;
             progression while on carfilzomib therapy after receiving at least two cycles of&#xD;
             treatment.&#xD;
&#xD;
          -  Patients with a complete response (CR) (including near CR and stringent CR) to&#xD;
             conventional induction therapy and proceeding to transplantation.&#xD;
&#xD;
          -  Pregnant or nursing females or women of reproductive capability who are unwilling to&#xD;
             use effective contraception. A woman of reproductive capability is one who has not&#xD;
             undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or&#xD;
             has not been post-menopausal (stopped menstrual periods) for more than 24 months in a&#xD;
             row.&#xD;
&#xD;
          -  Male subjects who refuse to practice effective barrier contraception during the entire&#xD;
             study treatment period and through a minimum of 30 days after the last dose of study&#xD;
             drug, or completely abstain from heterosexual intercourse. This must be done even if&#xD;
             they are surgically sterilized (ie, post-vasectomy).&#xD;
&#xD;
          -  Patient with Grade 2 peripheral neuropathy&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Patient had myocardial infarction within 6 months prior to enrollment or has New York&#xD;
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities.&#xD;
&#xD;
          -  Prior to study entry, any ECG abnormality at screening must be documented by the&#xD;
             investigator as not medically relevant.&#xD;
&#xD;
          -  Known allergies to any of the components of the investigational treatment regimen or&#xD;
             required ancillary treatments.&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 3 years of enrollment (with the&#xD;
             exception of non-melanoma skin cancer).&#xD;
&#xD;
          -  Participation in clinical trials with other investigational agents not included in&#xD;
             this trial, within 14 days of the start of this trial and throughout the duration of&#xD;
             this trial.&#xD;
&#xD;
          -  Prisoner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muneer H Abidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spectrum Health Hospitals</investigator_affiliation>
    <investigator_full_name>Muneer H. Abidi</investigator_full_name>
    <investigator_title>Adult Blood and Marrow Transplant Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

